TY - JOUR
T1 - Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans
AU - Feldmesser, Marta
AU - Kress, Yvonne
AU - Casadevall, Arturo
N1 - Funding Information:
Received 28 August 1997; revised 2 December 1997. Animal studies were performed in accordance with animal experimentation guidelines of the Albert Einstein College of Medicine. Financial support: NIH (AI-01341 to M.F., and AI-22774, AI-13342, and HL-59842 to A.C.); Burroughs Wellcome Fund Developmental Therapeutics Award (to A.C.). Reprints or correspondence: Dr. Marta Feldmesser, Albert Einstein College of Medicine, Golding Bldg. Room 701, 1300 Morris Park Ave., Bronx, NY 10461 (feldmess@aecom.yu.edu).
PY - 1998
Y1 - 1998
N2 - The effect of the murine IgG1 monoclonal antibody (MAb) 2H1, which binds to Cryptococcus neoformans glucuronoxylomannan (GXM), on pulmonary infection in immunocompetent C57Bl/6 mice was examined. C57Bl/6 mice develop eosinophilic pneumonia in response to pulmonary cryptococcal infection. Survival, organ fungus burden, serum anticapsular antibody levels, and histopathology by light and electron microscopy were studied. MAb administration prior to infection prolonged survival without reducing the number of yeast in the lung or extrapulmonary sites. Compared with uninfected mice, occasional control and MAb-treated mice produced more IgM antibody to GXM or low levels of GXM-binding IgG1, IgG2b, or IgG3 antibodies. MAb- treated mice had fewer granules per eosinophil, indicating alteration in eosinophil physiology or degranulation (or both). Our results provide additional evidence that antibody administration can produce quantitative and qualitative changes in the inflammatory response to a pathogen.
AB - The effect of the murine IgG1 monoclonal antibody (MAb) 2H1, which binds to Cryptococcus neoformans glucuronoxylomannan (GXM), on pulmonary infection in immunocompetent C57Bl/6 mice was examined. C57Bl/6 mice develop eosinophilic pneumonia in response to pulmonary cryptococcal infection. Survival, organ fungus burden, serum anticapsular antibody levels, and histopathology by light and electron microscopy were studied. MAb administration prior to infection prolonged survival without reducing the number of yeast in the lung or extrapulmonary sites. Compared with uninfected mice, occasional control and MAb-treated mice produced more IgM antibody to GXM or low levels of GXM-binding IgG1, IgG2b, or IgG3 antibodies. MAb- treated mice had fewer granules per eosinophil, indicating alteration in eosinophil physiology or degranulation (or both). Our results provide additional evidence that antibody administration can produce quantitative and qualitative changes in the inflammatory response to a pathogen.
UR - http://www.scopus.com/inward/record.url?scp=0031799529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031799529&partnerID=8YFLogxK
U2 - 10.1086/515314
DO - 10.1086/515314
M3 - Article
C2 - 9607844
AN - SCOPUS:0031799529
SN - 0022-1899
VL - 177
SP - 1639
EP - 1646
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -
